Congress Partners and Sponsors

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

INNOVATIVE MEDICINES

We have a presence in approximately 100 countries and regions worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Our medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available.

In Australia, CSL Seqirus is one of the largest influenza vaccine providers, a leader in iron deficiency and has a rapidly growing presence in nephrology. We are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.

CSL Seqirus is proud to sponsor local medical education and invest in research and development to help patients lead better, healthier lives.

We are a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark.

Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat.

We employ more than 77,000 people in 80 offices around the world, and market our products in 170 countries.

At Sobi, we are transforming the lives of people affected by rare diseases. As a specialised biopharmaceutical company, we provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases – a rare expertise and a strength in access that allows us to be a partner in care for those with high unmet needs. With our long-standing commitment to haematology, immunology, and rare metabolic diseases, our expansion into nephrology is a natural next step, given the inextricable link between these disease areas.

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies in areas of high unmet medical need.  Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain

Our innovations transform over a million Australians’ lives. In 2023, Boehringer invested 5.2 billion euros globally – including Australia – into making breakthroughs in areas including cardio-renal-metabolic and respiratory diseases, cancer, and mental health.

Pharmacor, an ANZ pharmaceutical company established in Australia in 2007, is a dynamic contributor in the complex field of generic medicine. We excel in detailed fixed-dose formulations, supplying a diverse range of prescription and OTC medications to pharmacies and hospitals nationwide. Our ambition is to lead the Australian generics market in a sustainable and environmentally conscious manner. Key to this is our strategy of introducing first-to-market generics, which bolsters competition while also enhancing the sustainability of the healthcare system by controlling costs.

In collaboration with Alkem Laboratories, we’re striving towards a future of sustainable and equitable healthcare. Our shared vision is to ensure all Australians have rapid access to affordable generic medicines, while we simultaneously uphold our commitment to environmental stewardship. Our strength is epitomised by our TGA & FDA approved research and manufacturing facilities, which operate with a keen focus on environmental responsibility.

We prioritise premium ingredients from certified suppliers, ensuring safe, effective medicines with minimal environmental impact. Our goal is to offer affordable alternatives for nephrology patients, easing hospital budgets while maintaining equivalent medical outcomes to brand-name drugs.

At Pharmacor, we are committed to not only delivering medicine, but also to fostering a healthier and greener future for our healthcare system.

A healthier future – that’s what drives us. Throughout our 128-year history, Roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas.  

Our commitment to our people, partners, stakeholders and, most importantly, patients remains as strong as it was on the rst day of our journey.  

At Roche, we are doing now what patients need next. We have a global ambition to deliver 20 transformative medicines by 2030, addressing diseases with the highest societal burden. Our focus is on end-to-end investment in 11 diseases across 5 therapy areas which account for the bulk of global disease burden: oncology & haematology, neurology, ophthalmology, immunology and cardiovascular-metabolism.  

With a heritage in respect for a healthy planet, Roche’s sustainability approach supports the UN Sustainable Development Goals. We are committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. 

Vantive, formerly part of Baxter, is proud to build on more than 70 years of leadership in Kidney Care, as an independent company focused on renal care.

We remain committed to preserving patient freedom through home dialysis,including peritoneal dialysis, with products and services designed to support high-quality care, supported by remote patient monitoring via our Sharesource platform and MyPD mobile app.

We continue to expand the potential of haemodialysis with HDx, enabled by our Theranova dialyser.

We are focused on enabling clinicians to provide the best treatment options possible and empowering patients through innovative therapies and models of care, digital solutions and advanced services.

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies in areas of high unmet medical need.  Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain

Our innovations transform over a million Australians’ lives. In 2023, Boehringer invested 5.2 billion euros globally – including Australia – into making breakthroughs in areas including cardio-renal-metabolic and respiratory diseases, cancer, and mental health.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. 

Building on a 40-year legacy that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, starting with kidney conditions that have significant unmet need. Historically, these conditions have had considerably less funding and research, leading to a treatment landscape largely focused on reactive or end-stage disease management, often with significant physical, emotional, and financial burdens. Our pipeline targets the underlying causes of disease, with an aim to protect kidney health and delay or prevent dialysis and/or transplantation. Our goal is to help patients get back to living life on their terms—whether at work, in school, or with loved ones, and by partnering with patients, advocates, clinicians and policymakers, we aim to raise awareness, accelerate diagnosis and get patients the right care, sooner. 

A healthier future – that’s what drives us. Throughout our 128-year history, Roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas.  

Our commitment to our people, partners, stakeholders and, most importantly, patients remains as strong as it was on the rst day of our journey.  

At Roche, we are doing now what patients need next. We have a global ambition to deliver 20 transformative medicines by 2030, addressing diseases with the highest societal burden. Our focus is on end-to-end investment in 11 diseases across 5 therapy areas which account for the bulk of global disease burden: oncology & haematology, neurology, ophthalmology, immunology and cardiovascular-metabolism.  

With a heritage in respect for a healthy planet, Roche’s sustainability approach supports the UN Sustainable Development Goals. We are committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. 

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

INNOVATIVE MEDICINES

We have a presence in approximately 100 countries and regions worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Our medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available.

About Medison Pharma
Medison is a global pharma company focused on providing access to highly innovative therapies to patients in international markets, with presence in Central and Eastern Europe, Canada, Latin America, Asia Pacific, Australia and Israel. Medison is the first to create a global commercialization platform for highly innovative therapies, helping to save and improve lives by making the best available novel treatments accessible to patients in international markets. Medison has a track record of global partnerships with leading pharmaceutical and biotech companies seeking to expand their global reach. 

To learn more visit www.medisonpharma.com. 

About Medison Pharma
Medison is a global pharma company focused on providing access to highly innovative therapies to patients in international markets, with presence in Central and Eastern Europe, Canada, Latin America, Asia Pacific, Australia and Israel. Medison is the first to create a global commercialization platform for highly innovative therapies, helping to save and improve lives by making the best available novel treatments accessible to patients in international markets. Medison has a track record of global partnerships with leading pharmaceutical and biotech companies seeking to expand their global reach. 

To learn more visit www.medisonpharma.com. 

About Medison Pharma
Medison is a global pharma company focused on providing access to highly innovative therapies to patients in international markets, with presence in Central and Eastern Europe, Canada, Latin America, Asia Pacific, Australia and Israel. Medison is the first to create a global commercialization platform for highly innovative therapies, helping to save and improve lives by making the best available novel treatments accessible to patients in international markets. Medison has a track record of global partnerships with leading pharmaceutical and biotech companies seeking to expand their global reach. 

To learn more visit www.medisonpharma.com. 

We are a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark.

Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat.

We employ more than 77,000 people in 80 offices around the world, and market our products in 170 countries.

At Sobi, we are transforming the lives of people affected by rare diseases. As a specialised biopharmaceutical company, we provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases – a rare expertise and a strength in access that allows us to be a partner in care for those with high unmet needs. With our long-standing commitment to haematology, immunology, and rare metabolic diseases, our expansion into nephrology is a natural next step, given the inextricable link between these disease areas.

At Sobi, we are transforming the lives of people affected by rare diseases. As a specialised biopharmaceutical company, we provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases – a rare expertise and a strength in access that allows us to be a partner in care for those with high unmet needs. With our long-standing commitment to haematology, immunology, and rare metabolic diseases, our expansion into nephrology is a natural next step, given the inextricable link between these disease areas.

About Medison Pharma
Medison is a global pharma company focused on providing access to highly innovative therapies to patients in international markets, with presence in Central and Eastern Europe, Canada, Latin America, Asia Pacific, Australia and Israel. Medison is the first to create a global commercialization platform for highly innovative therapies, helping to save and improve lives by making the best available novel treatments accessible to patients in international markets. Medison has a track record of global partnerships with leading pharmaceutical and biotech companies seeking to expand their global reach. 

To learn more visit www.medisonpharma.com. 

At AstraZeneca Australia and New Zealand, we have been working to deliver life-changing medicines to patients for more than 60 years. 

AstraZeneca is a global, science-led biopharmaceutical company engaged in the research, development, manufacture and supply of medicines that aim to make a real difference to the lives of Australians and New Zealanders. Our areas of focus include four therapy areas – Oncology; Cardiovascular, Renal and Metabolism (CVRM); and Respiratory and Immunology (R&I).  

We build our own capabilities by collaborating with world-renowned scientists, academic institutions, and like-minded, science-led companies.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. 

Building on a 40-year legacy that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, starting with kidney conditions that have significant unmet need. Historically, these conditions have had considerably less funding and research, leading to a treatment landscape largely focused on reactive or end-stage disease management, often with significant physical, emotional, and financial burdens. Our pipeline targets the underlying causes of disease, with an aim to protect kidney health and delay or prevent dialysis and/or transplantation. Our goal is to help patients get back to living life on their terms—whether at work, in school, or with loved ones, and by partnering with patients, advocates, clinicians and policymakers, we aim to raise awareness, accelerate diagnosis and get patients the right care, sooner. 

Alexion, AstraZeneca Rare Disease is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and delivery of life-changing medicines. A pioneering leader in rare disease for more than three decades, Alexion was the first to translate the complex biology of the complement system into transformative medicines, and today it continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities. As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US. Please visit https://alexion.com/worldwide/Australia. 

AU/NP/0021 

At Biogen, we are driven by a deep commitment to making a meaningful difference and are humbled by the opportunity to change lives. For more than 45 years, our scientific expertise has delivered treatment options for people living with rare and complex diseases. Building on this legacy, we are excited to be expanding our commitment to nephrology, advancing research in immune-mediated kidney diseases. We work closely with communities, healthcare professionals and researchers, and aim to support people beyond our medicines, globally and locally.

Creating a future worth living. For patients. Worldwide. Every day. 

Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 4,5 million patients worldwide regularly undergo dialysis treatment. 

We offer products and services along the entire dialysis value chain from a single source. As of December 31, 2025, we cared for more than 292,000 patients in our global network of roughly 3,600 dialysis centers worldwide. At the same time, we operated around 35 production sites on all continents, to provide dialysis products such as dialysis machines, dialyzers and related disposables.

We are a focused biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade with ambitious plans for growth and continuing to make GSK a company where everyone can thrive. 

We prevent and treat disease with vaccines, specialty medicines and general medicines. 

We focus on the science of the immune system and advanced technologies, investing in four core therapeutic areas (infectious diseases; respiratory, immunology and inflammation; oncology; and HIV) to impact health at scale. 

We operate responsibly for all our stakeholders by prioritising Innovation, Performance and Trust. 

For more information visit au.gsk.com. 

Simul Health is a Melbourne-based health technology company delivering purpose-built workflow and clinical coordination software for outpatient services across public and private hospitals in Australia and New Zealand. Our flagship platform, Simul Acute, extends across all outpatient specialties, with renal and oncology as most established deployments. For renal teams, Simul Acute manages the full patient journey, coordinates MDT meetings, integrates directly with hospital EMRs, and holds a certified, direct integration to the ANZDATA registry, removing manual re-entry. An AI-powered audio layer captures clinical conversations to streamline documentation and reduce administrative burden. We also offer Interoper8, our health data interoperability platform.

STADA Pharmaceuticals Australia 

STADA Australia is a specialty pharmaceutical company operating across the fields of neurology and nephrology in Australia and New Zealand. We are part of a global pharmaceutical group founded more than 125 years ago, with offices in over 30 countries and high‑quality, innovative pharmaceutical products available in approximately 120 countries. 

At STADA Australia, we are dedicated to supplying innovative therapies for chronic and serious medical conditions, with a focus on improving the treatment and quality of life of people living with Parkinson’s disease and chronic kidney disease. We understand the importance of partnering with healthcare professionals to support patients and carers through the provision of specialist products, services and ongoing education. 

STADA supplies VAFSEO® (vadadustat) for the treatment of anaemia associated with chronic kidney disease in appropriate adult patients. 

The Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry is a clinical quality registry dedicated to collecting, analysing, and reporting data on kidney replacement therapy across Australia and Aotearoa New Zealand. Established in 1977, ANZDATA is celebrating 50 years of enhancing patient care, informing clinical practices, and guiding health policy.

The Australasian Kidney Trials Network (AKTN) is a not-for-profit research organisation that designs, conducts and supports investigator-initiated clinical trials with the aim of improving life for people with Chronic Kidney Disease (CKD).

The National Indigenous Kidney Transplantation Taskforce (NIKTT) was established to improve access to kidney transplantation for Aboriginal and Torres Strait Islander peoples. As NIKTT’s funded program winds down, ANZSN 2026 offers an opportunity to engage the clinical community in shaping what comes next for this critical work.

The George Institute for Global Health is a leading independent, not-for-profit medical research organization, with offices in Australia, the UK, and India, and over 400 active projects across over 60 countries. It aims to improve the health of people worldwide through delivery of better treatment, better care and healthier societies.

Transplant Australia is the national charity supporting everyone on the transplant journey – including recipients, people waiting, donor families, living donors, and carers.  Through advocacy, resources, community engagement, peer support and active lifestyle programs we provide connection and guidance for a life lived well, while encouraging all Australians to embrace organ and tissue donation.